Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Clinical trial NCT06532643 · RECRUITING
Trial details
- NCT number
- NCT06532643
- Sponsor
- Shanghai First Song Biotechnology Co., LTD
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-24
- Primary completion
- 2025-09-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.